82 FR 240 pgs. 59622-59623 - Issuance of Priority Review Voucher; Rare Pediatric Disease Product

Next Article Next

Type: NOTICEVolume: 82Number: 240Pages: 59622 - 59623

Docket number: [Docket No. FDA-2017-N-0809]

FR document: [FR Doc. 2017-27049 Filed 12-14-17; 8:45 am]

Agency: Health and Human Services Department

Sub Agency: Food and Drug Administration

Official PDF Version: PDF Version

Pages: 59622, 59623

[top]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0809]

Issuance of Priority Review Voucher; Rare Pediatric Disease Product

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

[top] The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to

the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Food and Drug Administration Safety and Innovation Act (FDASIA), authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that MEPSEVII (vestronidase alfa-vjbk), manufactured by Ultragenyx Pharmaceutical, Inc., meets the criteria for a priority review voucher.

FOR FURTHER INFORMATION CONTACT:

Althea Cuff, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-4061, Fax: 301-796-9856, email: althea.cuff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

FDA is announcing the issuance of a priority review voucher to the sponsor of an approved rare pediatric disease product application. Under section 529 of the FD&C Act (21 U.S.C. 360ff), which was added by FDASIA, FDA will award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA has determined that MEPSEVII (vestronidase alfa-vjbk), manufactured by Ultragenyx Pharmaceutical, Inc., meets the criteria for a priority review voucher. MEPSEVII (vestronidase alfa-vjbk) is indicated for the treatment of Mucopolysaccharidosis type VII (MPS VII, Sly Syndrome).

For further information about the Rare Pediatric Disease Priority Review Voucher Program and for a link to the full text of section 529 of the FD&C Act, go to https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/RarePediatricDiseasePriorityVoucherProgram/default.htm. For further information about MEPSEVII (vestronidase alfa-vjbk), go to the "Drugs@FDA" website at https://www.accessdata.fda.gov/scripts/cder/daf/.

Dated: December 12, 2017.

Leslie Kux,

Associate Commissioner for Policy.

[FR Doc. 2017-27049 Filed 12-14-17; 8:45 am]

BILLING CODE 4164-01-P